Biohaven Ltd. (NYSE:BHVN) to Post FY2023 Earnings of ($4.53) Per Share, Cantor Fitzgerald Forecasts

Biohaven Ltd. (NYSE:BHVN – Get Rating) – Cantor Fitzgerald raised their FY2023 EPS estimates for Biohaven in a report issued on Tuesday, May 16th. Cantor Fitzgerald analyst C. Duncan now anticipates that the company will post earnings per share of ($4.53) for the year, up from their prior forecast of ($4.92). Cantor Fitzgerald has a “Overweight” rating and a $31.00 price objective on the stock. The consensus estimate for Biohaven’s current full-year earnings is ($5.25) per share.

BHVN has been the topic of several other research reports. SVB Securities began coverage on shares of Biohaven in a research note on Tuesday, January 24th. They set an “outperform” rating and a $24.00 price target on the stock. SVB Leerink reaffirmed an “outperform” rating and set a $24.00 price target on shares of Biohaven in a research note on Tuesday, January 24th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $38.39.

Biohaven Trading Up 1.7 %

Shares of BHVN stock opened at $14.10 on Friday. The company’s fifty day simple moving average is $13.73 and its 200-day simple moving average is $15.11. Biohaven has a 52 week low of $5.54 and a 52 week high of $20.57. The company has a market cap of $961.90 million, a PE ratio of -1.15 and a beta of 1.04.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of BHVN. US Bancorp DE boosted its holdings in shares of Biohaven by 19.1% in the 1st quarter. US Bancorp DE now owns 586 shares of the company’s stock valued at $70,000 after buying an additional 94 shares during the period. Cetera Advisor Networks LLC acquired a new position in Biohaven during the 1st quarter valued at about $332,000. AlphaCrest Capital Management LLC acquired a new position in Biohaven during the 1st quarter valued at about $344,000. BlackRock Inc. boosted its stake in Biohaven by 0.5% during the 1st quarter. BlackRock Inc. now owns 4,656,866 shares of the company’s stock valued at $552,163,000 after purchasing an additional 21,586 shares during the period. Finally, Dimensional Fund Advisors LP boosted its stake in Biohaven by 55.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 82,599 shares of the company’s stock valued at $9,794,000 after purchasing an additional 29,413 shares during the period. 98.01% of the stock is owned by institutional investors and hedge funds.

Biohaven Company Profile

(Get Rating)

Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an irreversible myeloperoxidase enzyme inhibitor for the treatment of neurodegenerative diseases.